Carbyne Equity Partners

Elicit Plant is an agro-biotech company focused on enhancing crops' resilience to water stress and developing innovative phytosterol-based solutions. By utilizing proprietary technology, the company aims to improve plant stress resistance and activate their natural defenses, addressing the global challenges posed by climate change in agriculture. Extensive field trials conducted across three continents have shown that Elicit Plant's biosolutions are effective, providing farmers with consistent and substantial returns on investment. Through its advancements, Elicit Plant seeks to lead the ecological transition in agriculture, ensuring that crops are better equipped to handle water shortages and contribute to sustainable farming practices.

Fotokite is a company focused on enhancing the capabilities of first responders through its innovative aerial robotics technology. The company has developed a patented system that can be installed on fire trucks and public safety vehicles, allowing firefighters to deploy a drone with the push of a button upon arriving at an incident scene. This drone, capable of reaching heights of up to 45 meters, provides real-time thermal and standard video feeds, enabling teams to quickly assess and visualize the situation without diverting additional personnel for piloting. The Fotokite system operates autonomously, utilizing a tether for power and data transmission, offering over 24 hours of flight time. Users can launch the drone via a tablet, adjusting altitude and camera angle as needed, while the aerial footage can be live-streamed to other responders on-site or back at the fire station. This functionality enhances situational awareness and facilitates more informed resource deployment during emergency events.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.